Guidelines for HER2 testing in breast cancer: A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)

Clinical and Translational Oncology

Volumn 11, Issue 6, 2009, Pages 363-375

  Albanell, Joan ^a   Andreu, Xavier ^c   Calasanz, María José ^d   Concha, Ángel ^e   Corominas, José María ^a   García Caballero, Tomás ^g   López, José Antonio ^h   López Ríos, Fernando ⁱ   Cajal, Santiago Ramóny ^j   Vera Sempere, Francisco J ^k   Colomer, Ramón ^f   Martín, Miguel ^h   Alba, Emilio ^l   González Martín, Antonio ^f   Llombart, Antonio ^m   Lluch, Ana ⁿ   Palacios, José ^b  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c Pathology Department   (Spain)

^d UNIVERSITY OF NAVARRA   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^f MD ANDERSON CANCER CENTER   (Spain)

^g University Hospital of Santiago de Compostela   (Spain)

^h HOSPITAL CLÍNICO SAN CARLOS   (Spain)

ⁱ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^j HOSPITAL GENERAL DE CATALUNYA   (Spain)

^k HOSPITAL UNIVERSITARIO LA FE   (Spain)

^l HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^m HOSPITAL ARNAU DE VILANOVA   (Spain)

ⁿ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

more..

Author keywords

Breast cancer; HER2; Immunohistochemistry; In situ hybridisation; Quality assurance; Standardisation

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ALGORITHM; ANALYTICAL EQUIPMENT; BREAST TUMOR; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; FEMALE; GENETICS; HEALTH CARE QUALITY; HOSPITAL DEPARTMENT; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LABORATORY DIAGNOSIS; MEDICAL RECORD; METHODOLOGY; MULTICENTER STUDY; ORGANIZATION AND MANAGEMENT; PAGET NIPPLE DISEASE; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PROTO ONCOGENE; REPRODUCIBILITY; SPAIN; STANDARD; STATISTICS;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLINICAL TRIALS, PHASE III AS TOPIC; DNA, NEOPLASM; FEMALE; FORMS AND RECORDS CONTROL; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MULTICENTER STUDIES AS TOPIC; PATHOLOGY DEPARTMENT, HOSPITAL; QUALITY ASSURANCE, HEALTH CARE; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SPAIN; SPECIMEN HANDLING;

EID: 73349106833     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-009-0370-6     Document Type: Article

References (37)

1. Akiyama T, Sudo C, Ogawara H et al (1986) The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644-1646. (Pubitemid 16095607)
2. Yarden Y (2001) Biology of HER2 and its importance in breast cancer. Oncology 61[SUPPL. 2]:1-13. (Pubitemid 33033419)
3. Yarden Y (2001) The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37[SUPPL. 4]:S3-8.
4. Rubin I, Yarden Y (2001) The basic biology of HER2. Ann Oncol 12[SUPPL. 1]:S3-8. (Pubitemid 32750577)
5. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182. (Pubitemid 17231334)
6. Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 3:237-252.
7. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18.
8. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145. (Pubitemid 350003059)
9. Baselga J, Tripathy D, Mendelsohn J et al (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744.
10. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792. (Pubitemid 32222155)
11. Cobleigh MA, Vogel CL, Tripathy D et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648. (Pubitemid 29415219)
12. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684. (Pubitemid 41464706)
13. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820. (Pubitemid 43290919)
14. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672. (Pubitemid 41464705)
15. Untch M, Gelber RD, Jackisch C et al (2008) Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 19:1090-1096. (Pubitemid 351796334)
16. Slamon DJ, Eiermann W, Robert NJ et al (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclphosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94[SUPPL. 1]:abstr 1.
17. Dawood S, Gonzalez-Angulo AM, Peintinger F et al (2007) Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. Cancer 110:1195-1200. (Pubitemid 47435588)
18. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733- 2743. (Pubitemid 46021510)
19. Von Minckwitz G, Zielinski C, Maarteense E et al (2008) Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG 26/BIG 3-05). J Clin Oncol 26:26.
20. Tan-Chiu E, Yothers G, Romond E et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819. (Pubitemid 46657378)
21. Perez EA, Suman VJ, Davidson NE et al (2008) Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238.
22. Paik S, Bryant J, Tan-Chiu E et al (2002) Realworld performance of HER2 testing: National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94:852-854. (Pubitemid 34705057)
23. Reddy JC, Reimann JD, Anderson SM, Klein PM (2006) Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer 7:153-157. (Pubitemid 44044012)
24. Hofmann M, Stoss O, Gaiser T et al (2008) Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol 61:89- 94. (Pubitemid 351158232)
25. Hanna W, O'Malley FP, Barnes P et al (2007) Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer. Curr Oncol 14:149-153.
26. Dowsett M, Hanby AM, Laing R, Walker R (2007) HER2 testing in the UK: consensus from a national consultation. J Clin Pathol 60:685-689. (Pubitemid 46975226)
27. Walker RA, Bartlett JMS, Dowsett M et al (2008) HER2 testing in the UK: further update to recommendations. J Clin Pathol 61:818-824. (Pubitemid 351969725)
28. Gancberg D, Di Leo A, Cardoso F et al (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13:1036-1043.
29. Kuukasjarvi T, Kononen J, Helin H et al (1996) Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14:2584-2589. (Pubitemid 26300127)
30. Cottu PH, Asselah J, Lae M et al (2008) Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol 19:595-597.
31. Werner M, Chott A, Fabiano A, Battifora H (2000) Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 24:1016-1019. (Pubitemid 30430490)
32. Haines GK III, Wiley E, Susnik B et al (2008) HER2 in well differentiated breast cancer: is testing necessary. Breast Cancer Res Treat 112:551- 556.
33. Bilous M, Dowsett M, Hanna W et al (2003) Current perspectives on HER2 testing: a review of National Testing Guidelines. Mod Pathol 16:173- 182. (Pubitemid 36245750)
34. Striebel JM, Bhargava R, Horbinski C et al (2008) The equivocally amplifi ed HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management. Am J Clin Pathol 129:383-390. (Pubitemid 352029290)
35. Ma Y, Lespagnard L, Durbecq V et al (2005) Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 11:4393-4399. (Pubitemid 40825629)
36. Persons DL, Tubbs RR, Cooley LD et al (2006) HER-2 fluorescence in situ hybridization. Results from the Survey Program of the College of American Pathologists. Arch Pathol Lab Med 130:325-331.
37. Tanner M, Gancberg D, Di Leo A et al (2000) Chromogenic in situ hybridization: a practical alternative for fl uorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 157:1467-1472.